Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice

Autor: Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Hirokazu Taniguchi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Thoracic Cancer, Vol 14, Iss 17, Pp 1618-1623 (2023)
Druh dokumentu: article
ISSN: 1759-7714
1759-7706
DOI: 10.1111/1759-7714.14907
Popis: Abstract Objective Studies have suggested the potential efficacy of immune checkpoint inhibitors (ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was conducted to evaluate the efficacy of systemic ICI therapy and chemoradiation followed by durvalumab therapy for pulmonary sarcomatoid carcinoma. Methods We analyzed the data of patients with pulmonary sarcomatoid carcinoma who received systemic ICI therapy or chemoradiation followed by durvalumab therapy between 2016 and 2022. Results In this study, data of a total of 22 patients who received systemic ICI therapy and four patients who received chemoradiation followed by durvalumab therapy were analyzed. In the patients who received systemic ICI therapy, the median progression‐free survival after initiation of therapy was 9.6 months, and the overall survival did not reach the median. The 1‐year progression‐free survival rate and overall survival rate were estimated to be 45.5% and 50.1%, respectively. Although the log‐rank test revealed no significant association between the tumor expression level of programmed death ligand‐1 (tumor proportion score evaluated using 22C3 antibody: ≥50% vs.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje